Expert Available for Comment on Black Women, Breast Cancer and Clinical Trials
Rutgers Cancer Institute of New Jersey
Children’s Hospital Los Angeles has launched the first clinical trial for Down syndrome regression disorder (DSRD), a rare and debilitating condition that affects adolescents and young adults with Down
X-linked adrenoleukodystrophy (X-ALD) is the most common of a group of around 50 rare diseases of the white matter of the brain, the so-called leukodystrophies.
A new clinical trial aims to shed light on how to best treat a patent ductus arteriosus in the most fragile infants.
New UCLA-led research suggests that antiretroviral drugs called TAF and TDF directly reduce energy production by mitochondria, structures inside cells that generate the power that cells use to function. Both drugs led to reduced cellular oxygen consumption rates, a measure of the ability of the mitochondria to produce energy, compared with controls.
Patients hospitalized with fractures typically receive an injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots.
Cedars-Sinai has appointed Michael E. Farkouh, MD, MSc, as associate dean for Research and Clinical Trials and professor of Cardiology, effective March 1, 2023. A clinical cardiologist and epidemiologist, Farkouh is internationally known for his academic leadership and distinguished record of diabetes and cardiovascular disease clinical trials.
A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study’s independent Data and Safety Monitoring Board. The investigational vaccine was generally safe and well tolerated; however, it was not effective at preventing the acquisition of HIV-1. The results of the uniquely designed and implemented Mosaico study underscore the challenges that have faced the global scientific community in the 40-year search for an HIV vaccine, and may provide important data in the ongoing fight against HIV.
The U.S. Food and Drug Administration (FDA) recently granted approval to Lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago.
Physician experts from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will be presenting the latest innovations in the study, diagnosis and treatment of gastrointestinal cancers at the ASCO GI Cancers Symposium from January 19-21.
Electronic nudges delivered to health care clinicians based on a machine learning algorithm that predicts mortality risk quadrupled rates of conversations with patients about their end-of-life care preferences, according to the long-term results of a randomized clinical trial published by Penn Medicine investigators in JAMA Oncology today.
For men who undergo radiotherapy for localized prostate cancer, the precise targeting capabilities of MRI guidance resulted in fewer toxicities and better quality of life according to new research from UCLA Jonsson Comprehensive Cancer Center.
Boiling peanuts for up to 12 hours could help overcome children’s allergic reactions according to the results of a clinical trial at Flinders University and SAHMRI which found up to 80% of children with peanut allergy became desensitised to eating peanuts.
The recently introduced thulium fiber laser (TFL) does not improve the clinical outcomes of laser treatment for urinary stones compared to the standard for laser stone therapy, reports a randomized trial in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.Over a decade ago, researchers from the University of Wisconsin–Madison developed a way to grow organized clusters of cells, called organoids, that resemble the retina, the light-sensitive tissue at the back of the eye.
A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.
A team from 15 U.S. medical centers led by UT Southwestern Simmons Cancer Center researchers has performed the first analysis of a potentially game-changing drug to treat upper urinary tract urothelial cancers.
Pain in the back or the neck is extremely common and accounts for more healthcare spending than any other health condition.
In a study examining the link between non-alcoholic fatty liver disease (NAFLD) and brain dysfunction, scientists at the Roger Williams Institute of Hepatology, affiliated to King’s College London and the University of Lausanne, found an accumulation of fat in the liver causes a decrease in oxygen to the brain and inflammation to brain tissue – both of which have been proven to lead to the onset of severe brain diseases.
Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States. Patients with the condition typically have inflammation throughout their esophagus and trouble swallowing food – known as dysphagia.Without proper treatment, the lining of the esophagus becomes fibrous, and the passage becomes so narrowed, or strictured, that food can lodge in the esophagus, requiring medical attention.
For selected patients with knee osteoarthritis, unicompartmental (or "partial") knee arthroplasty (UKA) shortens the recovery time for two key measures of physical function, as compared with total knee arthroplasty (TKA), reports a randomized trial in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center.
An international research group including scientists from Italy, the United States, Ireland, and Israel have published a three-year analysis of the Mesothelioma (Me) drug trial, Check-Mate 743 (CM-743).
Susan G. Komen and Guardant Health have formed a new partnership to help improve breast cancer outcomes by including the input of patient advocates. These advocates, who serve as Susan G. Komen Advocates in Science, will provide a first-hand understanding of what matters most to patients in the development of research studies to find more effective ways to care for patients with early-stage breast cancer.
Stressed university students might want to add walnuts to their daily diet in the weeks leading up to their next exam, according to new findings from a University of South Australia study published in Nutrients.
With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment.
Dr. Ryan Kaple joins structural heart colleagues Dr. Tilak Pasala and Dr. Lucy Safi to offer advanced clinical trials and surgical systems that enhance patient outcomes
Alzheimer’s disease (AD) is the fifth leading cause of death in adults over 65 years old. While many potential treatments for the neurodegenerative disease focus on developing drugs to target key culprits, a relatively new approach aims to more directly treat the brain.
Researchers at The Tisch Cancer Institute at Mount Sinai have identified a treatment that is effective and safer than the standard of care for a serious, and sometimes fatal, side effect of bone marrow transplant in cancer patients. Results from a phase 2 clinical trial were presented at the annual meeting of the American Society of Hematology (ASH) in December.
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Rutgers Cancer Institute of New Jersey and Tufts Medical Center Collaboration Published in Journal of Clinical Oncology
A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Researchers from the University of Pennsylvania’s Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract 2016).
Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped
Researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will be presenting data on the latest advances in blood cancer research and treatment at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13.
The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer’s disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as “preclinical” AD.
The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.
While people with cancer have options to participate in cancer clinical trials (CCTs), it can be challenging when they encounter difficulties enrolling and remaining in the trial. Trial withdrawal, although every participant’s right, can thwart study goals and hamper advancing novel treatments.
Chronic venous insufficiency (CVI) is a vascular condition affecting millions of people in the United States in which veins in the leg cannot efficiently carry blood back to the heart for oxygenation. For patients suffering from the condition, malfunctioning valves can cause blood to flow backwards and pool in the veins in the legs, which can lead to significant downstream affects for some people.
A newly updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy and systemic therapy after surgery to treat patients with endometrial cancer. The guideline also considers the role of surgical staging and molecular profiling techniques in determining whether a patient should receive post-operative therapy. The guideline is published in the January/February 2023 issue of Practical Radiation Oncology.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.
Researchers from the Desai Sethi Urology Institute, part of the University of Miami Miller School of Medicine, have launched a study to determine if wearing virtual reality headsets during in-office vasectomy helps relieve patients of procedure-related pain and anxiety.
People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.
A new trial will test whether a medication that targets gut bacteria can also improve irritability in teenagers with autism spectrum disorder.
Researchers at The Tisch Cancer Institute uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results published in JAMA Network Open in December.
SEATTLE — Dec. 1, 2022 — The 64th Annual Meeting and Exposition of the American Society of Hematology (ASH) will take place virtually and in person Dec. 10-13 in New Orleans, Louisiana.
A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and another blood test that is optimal for detecting relevant treatment effects.
The 2023 American Urological Association Gold Cystoscope Award has been awarded to Ranjith Ramasamy, M.D., associate professor and director of the University of Miami Miller School of Medicine Reproductive Urology Program and urologist within the Desai Sethi Urology Institute. Dr. Ramasamy has earned the honor for his commitment to education and mentorship.